The U.S. Food and Drug Administration (FDA) on Monday authorized a booster shot of Pfizer’s COVID-19 vaccine for children 12 to 15. The agency said that its scientists determined the booster’s benefits, including bolstering protection against virus infection, outweigh its potential risks in the population. Reviewers analyzed data from Israel, one of the most vaccinated countries in the world, to reach the conclusion. The dataset from Israel included information on more than 6,300 children 12 through 15 who received a booster dose. “The data shows there are no new safety concerns following a booster in this population. There were no new cases of myocarditis or pericarditis reported to date in these individuals,” the FDA said in a statement. Myocarditis and pericarditis are two forms of heart inflammation seen at much higher than expected rates among young people, particularly young men, following vaccination with the Pfizer or Moderna COVID-19 vaccines. The risk …